Shots:
- The UK’s MHRA has accepted MAA of AVT23, a proposed biosimilar of Xolair (omalizumab) for the treatment of severe persistent allergic asthma & CRSwNP
- Alvotech & Advanz Pharma entered into a commercialization agreement for AVT23 in Feb 2023, expanding their alliance in May to incl. 5 more biosimilars, whereas in Oct 2023, Alvotech & Kashiv signed a licensing agreement for AVT23
- Omalizumab is a humanized mAb that binds to free IgE to produce an anti-inflammatory action in allergic asthma & CRSwNP
Ref: Alvotech | Image: Alvotech & Kashiv & Advanz
Related News:- Alvotech and Dr. Reddy’s Report the US FDA’s BLA Acceptance for AVT03 (Biosimilar, Prolia and Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
